David Brindley

David is an international thought-leader in the translation of life-science innovations into commercially viable products and services. His expertise spans the ‘Valley of Death,’ encompassing regulation, basic science, process engineering and finance. This distinctive skill set positions David at the forefront of socially responsible investments – in particular initiatives that make impactful contributions to global health. David currently holds a joint appointment between the University of Oxford and the Harvard Stem Cell Institute and is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. In addition to being an Editorial Board member of a range of international academic and industrial journals, David is also a founder of Translation Ventures, a boutique consultancy that is actively engaged in maximizing the financial and societal value realized from cutting edge scientific innovations. Disclosure: David A Brindley has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in any postings apart from those disclosed. D.A.B. is subject to the CFA Institute’s Codes, Standards, and Guidelines, and as such, the author must stress that his contributions to this site are provided for academic interest only and must not be construed in any way as an investment recommendation.

Posts by: David


If cell therapy isn’t about the cells or the therapy, what is it about?

Author: David Brindley, 11/19/14

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate.   Both the IBC Cell Therapy Bioprocessing (ICTB) conference and the Stem Cells and Regenerative Medicine Congress (SCRMC) took place recently. The conferences shared several common themes: one being the presence of a significant focus…Read more

Revolution and reimbursement in the cell therapy industry

Author: David Brindley, 11/13/14

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate   In the early 1770s, Britain faced a significant financial dilemma. One of its most important commercial institutions, the East India Company, had come into considerable financial problems; a large quantity of tea was being…Read more

Of seismic waves and closing days: take home messages

Author: David Brindley, 10/01/14

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. There were two momentous events on the night of August 23, 2014. First, the inaugural Rejuvenation Biotechnology conference drew to a close. Second, the largest earthquake in nearly 25 years…Read more

Explosive growth in cell therapy just around the corner?

Author: David Brindley, 09/23/14

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute.   Assume a single bacterium weighs one thousand billionth of a gram. If it, and each of its progeny, divides once every 20 minutes then the population will reach approximately…Read more

Life, death and regulation

Author: David Brindley, 09/16/14

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute.   Consider this question: if I gave you the option to take a drug offering a 100 percent chance of survival to average life expectancy at which time you would…Read more

CRISPR and Rejuvenation Biotechnology: have you been hiding under a rock?

Author: David Brindley, 09/09/14

. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute.   ‘Bay Area biotechnology’ is a description that conjures images of the proud Hoover Tower at Stanford, and the iconic Genentech sign marking “Birthplace of Biotechnology,” set against the backdrop…Read more

Cell Therapy Industry 2027: It’s not all about therapies

Author: David Brindley, 10/25/13

. Nestled in the bosom of the Canadian Rockies, the global regenerative medicine community is assembled. Coaches laden with young investigators sporting impractically packed posters and drawn, jet lagged expressions are arriving in a steady procession. The usually sleepy pre-ski-season Banff is energized by stellar stem cell science and the expectation of its translation into…Read more

Cell Therapy Industry 2027: Managing expectation through effective communication

Author: David Brindley, 10/24/13

. 9am, Day 1: IBC Cell Therapy Bioprocessing Conference (Bethesda, MD, USA): Attempting to sharpen tie, and my welcome isolation is interrupted by a lady entering the elevator and fighting for mirror space. Cue small talk: “That’s a nice tie.” “Erm, thank you.” “And what is ‘bio…processing?’” [staring at name badge]. “Oh, I thought that…Read more

Cell Therapy Industry 2027: A Vernian Voyage

Author: David Brindley, 10/23/13

. The Cell Therapy Industry’s equivalent of ‘Wimbledon Fortnight,’ is upon us: ARM’s successfully delivered Meeting on the Mesa (La Jolla, CA) has served as a tantalizing hors d’oeuvre to IBC’s Cell Therapy Bioprocessing Conference (Bethesda, MD) and CCRM’s and SCN’s Till & McCulloch Meetings (Banff, Alberta). The trio of meetings are united in their…Read more

From Japan with love: Cell therapy intellectual property prospects

Author: David Brindley, 07/09/13

. At the close of ISSCR2013, I left Boston bathed in an ochre sunset, and settled on a plane to reflect on what my most unexpected learning had been. My plane was bound not for home (London), but for Istanbul, where the TERMIS meeting was about to begin. As far as I’m aware, the last…Read more